As shown in Table 1, increased XRCC2 showed a prolonged PFS in ovarian carcinoma patients with grade I (HR=0.17 (0.05-0.56), P=0.0009), as well as a better PFS and OS in grade III ovarian carcinoma patients (PFS: HR=0.76 (0.63-0.91), 0.0026; OS: HR=0.8 (0.67-0.96), P=0.016). This evidence concerns the gene XRCC2 and ovarian carcinoma.